OECD study finds no direct link between advertising rules and biosimilar uptake

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

OECD study finds no direct link between advertising rules and biosimilar uptake

Biosimilars/Research | Posted 13/03/2026 0 Post your comment

In December 2025, the Organisation for Economic Co-operation and Development (OECD) published a working paper titled ‘Assessing the impact of promotion and advertising regulations on biosimilar uptake’ [1].

The working paper highlights that, while biosimilar competition has generated substantial savings in Europe, uptake varies across OECD countries and therapeutic areas. The question of how regulation of promotion influences competition between biosimilars and their reference medicines has received limited attention in the literature. This paper examines the effects of advertising and promotional regulations on biosimilar uptake.

The authors conducted a review of national frameworks and held consultations with 29 key stakeholders in seven countries: Australia, Belgium, Denmark, France, Germany, Italy, and South Korea. Additionally, they carried out an analysis of biosimilar uptake in oncology, rheumatology, and diabetes, focusing on market share and spending to identify links between regulatory stringency and adoption patterns.

The findings indicate that conventional promotional activities—such as direct-to-consumer advertising, detailing, and sponsorships—are generally subject to strict regulation, whereas less conventional activities aimed at patient organisations, healthcare providers, and researchers have less oversight.

The study found no clear association between the stringency of promotional regulation and biosimilar uptake. Instead, broader supply- and demand-side policies related to procurement, pricing, and prescribing appear to have a greater influence. It is likely that originator companies retain significant competitive advantages through financial incentives, proprietary delivery devices, and digital tools.

Overall, the findings indicate that while promotional regulation plays a role, comprehensive policy frameworksare necessary to support the adoption of biosimilars.

LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Directriz estadounidense para eliminar los estudios comparativos de eficacia de los biosimilares

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Directriz estadounidense para eliminar los estudios comparativos de eficacia de los biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Reference
1. Barrenho, E. et al. (2025), Assessing the impact of promotion and advertising regulations on biosimilar uptake, OECD Health Working Papers, No. 186, OECD Publishing, Paris, https://doi.org/10.1787/c69f54b2-en

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.